Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $223000.0.

  • Utah Medical Products' Non-Current Deferred Tax Liability fell 2202.8% to $223000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $223000.0, marking a year-over-year decrease of 2202.8%. This contributed to the annual value of $469000.0 for FY2024, which is 4565.22% up from last year.
  • Utah Medical Products' Non-Current Deferred Tax Liability amounted to $223000.0 in Q3 2025, which was down 2202.8% from $370000.0 recorded in Q2 2025.
  • Utah Medical Products' 5-year Non-Current Deferred Tax Liability high stood at $638000.0 for Q1 2023, and its period low was $208000.0 during Q2 2024.
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $469000.0 (2024), whereas its average is $443736.8.
  • As far as peak fluctuations go, Utah Medical Products' Non-Current Deferred Tax Liability plummeted by 6687.9% in 2024, and later surged by 7788.46% in 2025.
  • Utah Medical Products' Non-Current Deferred Tax Liability (Quarter) stood at $577000.0 in 2021, then dropped by 4.85% to $549000.0 in 2022, then plummeted by 41.35% to $322000.0 in 2023, then surged by 45.65% to $469000.0 in 2024, then tumbled by 52.45% to $223000.0 in 2025.
  • Its Non-Current Deferred Tax Liability was $223000.0 in Q3 2025, compared to $370000.0 in Q2 2025 and $385000.0 in Q1 2025.